Optimizing the Adipogenic Induction Protocol Using Rosiglitazone Improves the Physiological Parameters and Differentiation Capacity of Adipose Tissue-Derived Mesenchymal Stem Cells for Horses, Sheep, Dogs, Murines, and Humans.
Authors: Heimann Manuela, Elashry Mohamed I, Klymiuk Michele C, Eldaey Asmaa, Wenisch Sabine, Arnhold Stefan
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Adipose tissue-derived mesenchymal stem cells (ASCs) hold considerable promise for regenerative medicine applications in equine and other veterinary contexts, yet establishing a standardised, non-toxic differentiation protocol across species has proven challenging. Researchers compared a rosiglitazone-based adipogenic induction protocol against the conventional IBMX (3-isobutyl-1-methylxanthine) approach across equine, ovine, canine, murine, and human ASC populations, measuring cell viability, cytotoxicity, lipid accumulation, and expression of key adipogenic markers (FABP-4 and leptin) over 14 days. The optimised rosiglitazone protocol at 5 µM concentration significantly outperformed IBMX induction, demonstrating superior cell viability and proliferation rates, larger lipid droplet formation, reduced apoptosis, and robust upregulation of adipogenic markers across most species tested—whilst the IBMX protocol induced marked cell death and reduced cell numbers. For equine practitioners, this work validates rosiglitazone as a superior, more reproducible methodology for generating metabolically active ASCs with potential applications in managing obesity and metabolic disease, offering a standardised framework that should improve consistency and efficacy in cell-based therapeutic approaches across species.
Read the full abstract on PubMed
Practical Takeaways
- •This research establishes a standardized, less toxic protocol for generating adipose-derived stem cells from horses and other species, potentially useful for future regenerative medicine applications in equine practice
- •The rosiglitazone protocol's improved cell viability and reduced toxicity may make it more suitable for developing reliable stem cell therapies across different animal species
- •While this is fundamental research, it could support future development of stem cell-based treatments for metabolic conditions in equine patients, though clinical applications remain distant
Key Findings
- •5 μM rosiglitazone protocol improved adipogenic differentiation in horse, sheep, and dog ASCs compared to IBMX protocol
- •Rosiglitazone increased cell viability and cell number while IBMX protocol showed marked reductions in both parameters
- •Rosiglitazone upregulated FABP-4 and Leptin expression in ASCs across most mammalian species tested
- •Rosiglitazone protocol demonstrated lower toxicity and better reproducibility than traditional IBMX induction method